---
title: "Maxim Group Initiates a Buy Rating on Polaryx Therapeutics, Inc. (PLYX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277507478.md"
description: "Maxim Group analyst Jason McCarthy has initiated coverage on Polaryx Therapeutics, Inc. (PLYX) with a Buy rating and a price target of $10.00. The analyst focuses on the Healthcare sector and has an average return of -16.9% with a 29.37% success rate on his stock recommendations. The current analyst consensus for Polaryx is a Moderate Buy, also with an average price target of $10.00."
datetime: "2026-03-02T18:36:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277507478.md)
  - [en](https://longbridge.com/en/news/277507478.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277507478.md)
---

# Maxim Group Initiates a Buy Rating on Polaryx Therapeutics, Inc. (PLYX)

Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Polaryx Therapeutics, Inc. on February 27 and set a price target of $10.00.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

McCarthy covers the Healthcare sector, focusing on stocks such as Aprea Therapeutics, Co-Diagnostics, and Plus Therapeutics. According to TipRanks, McCarthy has an average return of \-16.9% and a 29.37% success rate on recommended stocks.

Currently, the analyst consensus on Polaryx Therapeutics, Inc. is a Moderate Buy with an average price target of $10.00.

### Related Stocks

- [PLYX.US](https://longbridge.com/en/quote/PLYX.US.md)

## Related News & Research

- [Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | PLYX Stock News](https://longbridge.com/en/news/282852650.md)
- [Polaryx Therapeutics (NASDAQ:PLYX) Trading 4.9% Higher   - Time to Buy?](https://longbridge.com/en/news/282762994.md)
- [Oruka Therapeutics (ORKA) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/282540371.md)
- [Capricor Therapeutics (CAPR) Gets a Buy from Roth MKM](https://longbridge.com/en/news/282746660.md)
- [RBC Capital Sticks to Their Buy Rating for Edwards Lifesciences (EW)](https://longbridge.com/en/news/282768248.md)